Addressing Concerns for Neoadjuvant Therapies in Locally Advanced Kidney Cancer

Martin H. Voss, MD

Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.

Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.

One of the biggest concerns with neoadjuvant approaches compared with adjuvant treatments for nonmetastatic disease is whether neoadjuvant therapies will delay the timing of surgeries, according to Voss. Most of the drugs used in the neoadjuvant setting have proven to work well with subsequent surgery and have not postponed timing.